Group 1 - The core viewpoint of the article is that the legal opinions regarding the 2024 annual shareholders' meeting of Runben Biotechnology Co., Ltd. confirm that the meeting's procedures, participant qualifications, and voting results comply with relevant laws and regulations [1][8]. Group 2 - The shareholders' meeting is scheduled for May 15, 2025, at 15:00 in Guangzhou, and was convened by the company's board of directors based on a prior board meeting decision [2][3]. - A total of 7 shareholders and their representatives attended the meeting, holding shares registered as of May 9, 2025 [3]. - The meeting allowed for both on-site and online voting, with specific timeframes for each voting method clearly communicated to shareholders [4][5]. Group 3 - The online voting involved 80 shareholders representing 24,125,909 shares, accounting for 5.9630% of the company's total share capital [5]. - The voting results from both on-site and online methods were combined, and the meeting's resolutions were signed by the attending board members [8]. Group 4 - The legal opinions affirm that the meeting's convening, participant qualifications, voting procedures, and results are all valid and comply with the company's articles of association and applicable laws [6][8].

Core Viewpoint - The company is planning to expand its production and research capabilities by investing in a new research and production base in Guangzhou, which is part of its C2M supply chain strategy aimed at increasing market share and competitive advantage [4][6][7]. Group 1: Meeting Information - The first extraordinary general meeting of shareholders for 2025 will be held on May 22, 2025, at 15:30 in Guangzhou [3]. - The meeting will include both on-site and online voting options for shareholders [3][4]. - The agenda includes signing an output input supervision agreement and discussing external investments [4][7]. Group 2: Investment Details - The company has acquired a land parcel (ZSCB-E3-4) of approximately 31,585 square meters for the new research and production base, which will be adjacent to another site (ZSCB-E3-3) [5][6]. - The planned investment for the new base is 600 million RMB, focusing on various functions including office, research, production, and employee facilities [6][7]. - The investment does not constitute a related party transaction or a significant asset restructuring as defined by regulations [7].

2025 年 5 月 16 日 1 润本生物技术股份有限公司 2025 年第一次临时股东大会会议资料 润本生物技术股份有限公司 2025 年第一次临时股东大会 会议资料 润本生物技术股份有限公司 2025 年第一次临时股东大会会议资料 目 录 | 2025 | 年第一次临时股东大会须知…………………………………………………3 | | --- | --- | | 2025 | 年第一次临时股东大会议程…………………………………………………5 | | | 议案一：关于签署投入产出监管协议暨对外投资的议案…………….………….7 | 2 润本生物技术股份有限公司 2025 年第一次临时股东大会会议资料 股东大会会议须知 为维护全体股东的合法权益，确保股东大会的正常秩序和议事效率，保证 大会的顺利进行，润本生物技术股份有限公司（以下简称"公司"），根据 《中华人民共和国公司法》《中华人民共和国证券法》《上市公司股东会规则》 等相关法律法规以及《公司章程》《公司股东大会议事规则》的规定，特制定 本须知： 一、董事会以维护股东的合法权益，确保股东大会正常秩序和议事效率为 原则，认真履行《公司章程》中规定的职责，做好召集、 ...

证券代码：603193 证券简称：润本股份 公告编号：2025-024 润本生物技术股份有限公司 2024年年度股东大会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次会议是否有否决议案：无 一、 会议召开和出席情况 (一)股东大会召开的时间：2025 年 5 月 15 日 (二)股东大会召开的地点：广东省广州市天河区珠江新城华夏路 28 号富力盈信 (一)非累积投票议案 1、 议案名称：《关于<2024 年年度报告及摘要>的议案》 审议结果：通过 大厦 40 楼润本生物技术股份有限公司会议室 (三)出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： | 1、出席会议的股东和代理人人数 | 87 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 317,935,109 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股 | | | 份总数的比例（%） | 78.5814 | (四)表决方式是否符合《公司法》及《公司章程》的规定，大会主持情 ...

广东广信君达律师事务所（以下简称"本所"）接受润本生物技术股份有限公司（以下简 称"公司"）的委托，指派许丽华、马小希律师（以下简称"本律师"）出席了公司于 2025 年 5 月 15 日（星期四）下午 15:00 在广东省广州市天河区华夏路 28 号富力盈信大厦 40 楼公 司会议室召开的 2024 年年度股东大会（以下简称"本次股东大会"），并依据《中华人民共 和国公司法》、《中华人民共和国证券法》、《上市公司股东会规则》、《上海证券交易所股 票上市规则》等中国现行法律、法规和其它规范性法律文件（以下合称"法律法规"）以及《润 本生物技术股份有限公司章程》（以下简称"公司章程"）的有关规定，就本次股东大会的召 集和召开程序、出席会议人员的资格和召集人资格、表决程序和表决结果等相关事宜出具法律 意见。 为出具本法律意见书，本律师听取了公司就有关事实的陈述和说明，审查了公司提供的相 关文件，包括但不限于： 1. 公司章程； 2. 第二届董事会第七次会议决议公告； 3. 公司于 2025 年 4 月 25 日在《证券时报》、《中国证券报》、《上海证券报》、巨潮 资讯网（http://www.cninfo.com ...

Investment Rating - The report maintains an "Overweight" rating for the industry [4][6]. Core Insights - The 618 promotional event has been advanced, with Tmall's pre-sale period shortened compared to the previous year's Double Eleven event. The first wave of Tmall's 618 sales runs from May 13 to May 26, 2025, with a pre-sale deposit payment phase from May 13 to May 16, and a final payment and early purchase phase from May 16 to May 26. This is a 7-day advance compared to last year's 618 event and a 4-day reduction compared to last year's Double Eleven pre-sale period [2][11]. - The promotional mechanisms have been simplified, with Tmall and JD.com eliminating cross-store discounts and increasing platform subsidies. Tmall's official discounts range from 15% to 50%, and the number of coupons issued to 88VIP members has increased significantly from 2 to 6 compared to last year [2][12]. - The first hour of sales in Li Jiaqi's live stream saw a GMV increase of over 10% year-on-year, with notable performances from domestic brands such as Proya and Kefu Mei [3][15]. Summary by Sections 1. 618 Promotional Event - The promotional event's schedule has been advanced, with Tmall's pre-sale period shortened compared to the previous year [2][11]. - JD.com has canceled the pre-heating period, maintaining the same sales period as last year [2][11]. 2. Li Jiaqi's Live Stream Sales Performance - The first hour of the "Explosive Beauty Festival" in Li Jiaqi's live stream saw a GMV increase of over 10% year-on-year, with multiple brand collaborations [3][15]. - Domestic brands such as Proya and Kefu Mei performed exceptionally well during the first day of sales [3][16]. 3. Tmall 618 Pre-sale Rankings - Proya ranked first in the beauty sales during the first four hours of Tmall's pre-sale, with Kefu Mei entering the top three [3][21]. - The rankings indicate a strong performance from domestic brands, with Proya maintaining its leading position and Kefu Mei rising three spots [3][21].

5月13日，南都·湾财社记者就财报情况及公司未来发展计划致电润本股份证券办，电话无人接听。随后 记者通过官方电子邮箱发送采访函，截至发稿尚未收到回复。 线上渠道占比超七成 驱蚊与婴童护理产品为核心增长引擎 近日，润本股份（603193.SH）发布2024年年度报告及2025年第一季度财报。数据显示，公司全年实现 营收13.18亿元，同比增长27.61%；归母净利润3亿元，同比增长32.8%。 | | | | | 单位:元 币种:人民币 | | --- | --- | --- | --- | --- | | 主要会计数据 | 2024年 | 2023年 | 本期比 上年同 期增减 | 2022年 | | | | | (%) | | | 营业收入 | 1.318.176.100.04 | 1.032.954.606.07 | 27.61 | 856,089,237.98 | | 归属于上市公司股东的净 | 300,161,748.03 | 226,027,081.04 | 32.80 | 160,044,939.47 | | 利润 | | | | | | 归属于上市公司股东的扣 | 289,229,513.93 ...

暗盘资金正涌入这些股票，点击速看>>> 美容护理板块震荡走高，拉芳家化（603630）涨停，水羊股份（300740）、芭薇股份、珀莱雅 （603605）、润本股份（603193）有所拉升。 ...

Summary of Conference Call Records Industry Overview - The beauty and personal care industry in China is experiencing significant growth, driven by domestic consumption and the expansion of domestic brands [1][2]. Key Company Insights Shangmei Co., Ltd. (上美股份) - **Sales Growth**: - Tmall sales increased by 30% - JD.com sales grew nearly 70% - Kuaishou and Pinduoduo saw growth between 150% to 200% [1] - **NewPage Performance**: - Q1 revenue reached 160 million, with a 100% growth rate - Expected profit margin improvement for the year [1] - **Product Launches**: - NanBeauty plans to launch mid-to-high-end cosmetics in the second half of the year - Jifang Hair Care is set to expand after obtaining necessary certifications [1] - **Douyin Growth**: - Sales recovery began in April, with an increase in self-broadcasting and improved profit margins [1] - **Marketing Strategy**: - X Peptide aims for a GMV of 1 billion, with new endorsements to enhance marketing effectiveness [1] - Increased brand promotion and collaborations with influencers, including Ding Yuxi as the global ambassador for Han Shu [1] Runben Co., Ltd. (润本股份) - **Revenue Growth**: - Overall revenue increased by approximately 30% in April, with online sales up by about 10% - Significant growth in offline non-platform distribution (toB business) exceeding 50%, particularly in the Sam's Club channel [2] - **Sales Performance**: - Sales in Sam's Club reached over 20 million in April, up from approximately 12 million in March [2] - **Future Projections**: - Anticipates a revenue growth of over 20% in Q2, maintaining a target of 30% growth for both revenue and profit for the first half of the year [2] Marubi Biotechnology Co., Ltd. (丸美生物) - **Q1 Performance**: - Revenue growth of 28% with a net profit increase of 22% [2] - **Annual Targets**: - Aiming for a 32% growth in net profit for the year, referencing the previous year's performance [2] - **Product Sales Forecast**: - Xiaohongbi Eye Cream projected to achieve over 500 million in sales for 2024, representing a 146% growth - Xiaojin Needle expected to reach 350 million in online sales, with a 96% increase, alongside a doubling of offline sales [2] Additional Insights - The emphasis on high-quality ingredients and effective products is becoming a key profitability driver for companies in the beauty sector [3]

Investment Rating - The investment rating for the retail industry is "Positive" (maintained) [1] Core Insights - The retail industry is experiencing a slow recovery in social consumption, with overall business pressure on retail enterprises. The report emphasizes the importance of emotional consumption and suggests focusing on high-quality companies in high-growth segments [4][27] - The report identifies key segments within the retail industry, including traditional retail, gold and jewelry, cosmetics, and medical aesthetics, each with unique dynamics and investment opportunities [4][27] Summary by Sections Retail Market Overview - The retail industry index rose by 0.88% during the week of May 6 to May 9, 2025, underperforming the Shanghai Composite Index, which increased by 1.92% [6][15] - The brand cosmetics sector showed the highest growth, with a weekly increase of 2.89% and a year-to-date increase of 15.91% [18][21] Investment Strategy - The report recommends focusing on high-quality companies in segments driven by emotional consumption, including: 1. **Gold and Jewelry**: Emphasizing brands with differentiated products and consumer insights, recommending companies like Laopuhuangjin, Chaohongji, and Zhou Dasheng [7][48] 2. **Offline Retail**: Highlighting companies that are actively transforming and exploring new models, recommending Yonghui Supermarket and Aiyingshi [7][48] 3. **Cosmetics**: Focusing on domestic brands with strong growth potential, recommending brands like Pola, Shangmei, and Juzi Biological [7][49] 4. **Medical Aesthetics**: Suggesting attention to differentiated product manufacturers and leading medical aesthetic institutions, recommending Aimeike and Kedi-B [7][49] Segment Analysis - **Traditional Retail**: The report notes that offline retail must leverage its strengths in customer service and emotional satisfaction to attract consumers back from online channels [4][28] - **Gold and Jewelry**: The industry is shifting from supply-driven to demand-driven, with emotional consumption becoming a key factor. High-end and fashionable gold segments are emerging as significant opportunities [4][36] - **Cosmetics**: The industry is stable in the short term, with a long-term trend favoring domestic brands. Emotional consumption is spreading across various cosmetic categories [4][41] - **Medical Aesthetics**: The industry is experiencing accelerated differentiation, with high-end products showing resilience due to their safety and scarcity [4][44]